PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30210625-11	2018	In colon cancer PDCs with NCOA4-RET fusion, vandetanib potently inhibited AKT and ERK phosphorylation.	vandetanib	44-54	nuclear receptor coactivator 4	Homo sapiens	26-31	
30210625-12	2018	This study shows that vandetanib might be one of useful treatment strategies for CRC patient with NCOA4-RET fusion.	vandetanib	22-32	nuclear receptor coactivator 4	Homo sapiens	98-103	
12499271-4	2002	ZD6474 blocked in vivo phosphorylation and signaling of the RET/PTC3 and RET/MEN2B oncoproteins and of an epidermal growth factor (EGF)-activated EGF-receptor/RET chimeric receptor.	vandetanib	0-6	nuclear receptor coactivator 4	Homo sapiens	64-68	
12499271-5	2002	RET/PTC3-transformed cells-treated ZD6474 lost proliferative autonomy and showed morphological reversion.	vandetanib	35-41	nuclear receptor coactivator 4	Homo sapiens	4-8